サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1777480

原発性免疫不全症の世界市場

Primary Immunodeficiency Disorders

出版日
ページ情報
英文 280 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.53円
原発性免疫不全症の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 280 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

原発性免疫不全症の世界市場は2030年までに104億米ドルに到達

2024年に79億米ドルと推定される原発性免疫不全症の世界市場は、分析期間2024-2030年にCAGR 4.8%で成長し、2030年には104億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである免疫グロブリン補充療法は、CAGR 3.8%を記録し、分析期間終了時には44億米ドルに達すると予測されます。抗生物質療法セグメントの成長率は、分析期間中CAGR 4.9％と推定されます。

米国市場は21億米ドルと推定、中国はCAGR 7.5％で成長予測

米国の原発性免疫不全症市場は2024年に21億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 7.5%で推移し、2030年までに20億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と4.8%と予測されています。欧州では、ドイツがCAGR 3.1%で成長すると予測されています。

世界の原発性免疫不全症（PID）市場- 主要動向と促進要因まとめ

なぜ原発性免疫不全症治療へのニーズが高まっているのか？

原発性免疫不全症（PID）は、感染に対する免疫系の防御能力を低下させ、罹患者を再発性の重症疾患に罹患しやすくする稀な遺伝子疾患群です。450を超えるPIDの病型が確認されており、効果的な診断ツールや治療法に対する需要は著しく高まっています。遺伝子検査や新生児スクリーニングプログラムの進歩により早期発見が改善され、重篤な合併症を予防するタイムリーな介入が可能となっています。PIDの治療法には、主に免疫グロブリン補充療法（IVIGおよびSCIG）、造血幹細胞移植（HSCT）、遺伝子治療があります。また、免疫不全の根底にある分子メカニズムが解明されつつあることから、標的生物学的製剤や免疫調節療法が開発され、より個別化された治療選択肢が提供されています。さらに、希少疾患研究に対する患者の支持と資金援助の増加により、治療へのアクセスを向上させ、治療パイプラインを拡大する取り組みが加速しています。ヘルスケアプロバイダーや政策立案者がPID管理を優先する中、診断および治療ソリューションの市場は大きく成長する見込みです。

PID治療の進歩を阻む課題とは？

PIDの診断や治療が進歩しているにもかかわらず、この分野へのアクセスや技術革新を制限している課題がいくつかあります。主な懸念事項の1つは、多くのPID患者にとって生涯必要となる免疫グロブリン補充療法にかかる費用の高さです。IVIG製造のためのドナー血漿の入手可能性が限られているため、供給がさらに制限され、定期的な不足と価格の変動につながっています。さらに、多くの症状が一般的な感染症や自己免疫疾患と重複しているため、診断が遅れたり見逃されたりすることがあります。また、規制上の障壁は、新たな遺伝子治療薬や生物製剤の承認を遅らせ、新たな治療法の市場投入までの時間を長期化させています。さらに、ヘルスケアインフラや診断能力における格差が、低所得地域におけるPID治療へのタイムリーなアクセスを妨げ、十分なサービスを受けていない人々の疾病負担を悪化させています。このような課題に対処するためには、代替治療法への投資を増やし、新生児スクリーニングプログラムを拡大し、アクセスと経済的負担を改善するために利害関係者間の連携を強化する必要があります。

遺伝子治療と免疫療法の技術革新はPID治療にどのような変化をもたらしているのか？

遺伝子治療と免疫調節治療における技術的進歩はPID治療の展望を変えつつあり、根治的かつ的を絞った治療アプローチを提供しています。遺伝子治療は、重症複合免疫不全症（SCID）や慢性肉芽腫性疾患（CGD）のような重症PIDの原因となる根本的な遺伝子変異を修正し、生涯にわたるIVIG療法の必要性を減らすという有望な結果を示しています。モノクローナル抗体やサイトカインベースの治療法の開発は、治療の選択肢をさらに広げ、特定の免疫不全サブタイプを持つ患者の免疫機能を調整するのに役立っています。さらに、プレシジョン・メディシンの進歩により、患者の層別化が進み、遺伝子プロファイルに基づいた最も効果的な治療が受けられるようになっています。AI主導の診断ツールと次世代シーケンサー（NGS）は、早期発見とリスク評価を改善し、積極的な治療計画を促進しています。遠隔医療とデジタル患者モニタリングの統合も疾病管理を強化し、ヘルスケア提供者が治療に対する患者の反応をリアルタイムで追跡できるようにしています。このような技術革新が進むにつれて、PID治療の未来はますます個別化され、効果的なものになっていくでしょう。

原発性免疫不全症市場の成長の原動力は？

原発性免疫不全症市場の成長は、希少な免疫疾患に対する認識の高まり、遺伝子診断の進歩、治療の選択肢の拡大など、いくつかの要因によって牽引されています。スクリーニングプログラムの改善により、PIDと診断される有病率が上昇していることが、免疫グロブリン療法や標的生物製剤の需要拡大に寄与しています。希少疾病研究や希少疾病用医薬品の開発を支援する政府のイニシアチブは市場拡大をさらに加速し、製薬企業に新規治療への投資を促しています。また、細胞治療や遺伝子治療の採用が拡大していることも、PID治療の展望を大きく変えつつあり、重症例に根治的な解決策を提供する可能性があります。さらに、患者支援団体や非営利団体が、研究資金の助成、診断サービスへのアクセスの強化、疾患認知度の向上において重要な役割を果たしています。治療の革新と世界のヘルスケア政策が進化を続ける中、原発性免疫不全症市場は、より効果的で利用しやすいケアソリューションへの道を開き、大幅な成長が見込まれています。

セグメント

治療タイプ（免疫グロブリン補充療法、抗生物質療法、幹細胞／骨髄移植、遺伝子療法、その他の治療タイプ）、疾患タイプ（抗体欠損症、細胞性免疫不全症、自然免疫疾患、その他の疾患タイプ）

調査対象企業の例

  • Abbott Laboratories
  • ADMA Biologics
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • CSL Behring LLC
  • GC Biopharma
  • Grifols S.A.
  • Horizon Therapeutics plc
  • Kedrion Biopharma Inc.
  • LFB S.A.
  • Lupin Pharmaceuticals
  • Merck KGaA
  • Novartis International AG
  • Octapharma AG
  • Pharming Group N.V.
  • Takeda Pharmaceutical Company Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32692

Global Primary Immunodeficiency Disorders Market to Reach US$10.4 Billion by 2030

The global market for Primary Immunodeficiency Disorders estimated at US$7.9 Billion in the year 2024, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Immunoglobulin Replacement Therapy, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Antibiotic Therapy segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 7.5% CAGR

The Primary Immunodeficiency Disorders market in the U.S. is estimated at US$2.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Primary Immunodeficiency Disorders (PID) Market - Key Trends & Drivers Summarized

Why Is There an Increasing Need for Primary Immunodeficiency Disorder Treatments?

Primary Immunodeficiency Disorders (PIDs) are a group of rare genetic conditions that impair the immune system’s ability to defend against infections, making affected individuals highly susceptible to recurrent and severe illnesses. With over 450 identified forms of PID, the demand for effective diagnostic tools and therapeutic solutions has risen significantly. Advances in genetic testing and newborn screening programs have improved early detection, enabling timely interventions that prevent severe complications. Treatment options for PIDs primarily include immunoglobulin replacement therapy (IVIG and SCIG), hematopoietic stem cell transplantation (HSCT), and gene therapy. The growing understanding of the molecular mechanisms underlying immunodeficiencies has also led to the development of targeted biologics and immunomodulatory therapies, offering more personalized treatment options. Additionally, increased patient advocacy and funding for rare disease research have accelerated efforts to enhance treatment accessibility and expand therapeutic pipelines. As healthcare providers and policymakers prioritize PID management, the market for diagnostic and therapeutic solutions is poised for significant growth.

What Challenges Are Hindering the Advancement of PID Therapies?

Despite advancements in PID diagnosis and treatment, several challenges continue to limit access and innovation in the field. One of the primary concerns is the high cost of immunoglobulin replacement therapy, which is a lifelong requirement for many PID patients. The limited availability of donor plasma for IVIG production further constrains supply, leading to periodic shortages and pricing fluctuations. Additionally, the complexity of diagnosing PIDs presents a significant hurdle, as many symptoms overlap with common infections or autoimmune diseases, resulting in delayed or missed diagnoses. Regulatory barriers also slow down the approval of emerging gene therapies and biologics, prolonging the time-to-market for new treatments. Furthermore, disparities in healthcare infrastructure and diagnostic capabilities prevent timely access to PID therapies in low-income regions, exacerbating disease burden in underserved populations. Addressing these challenges requires increased investment in alternative treatment approaches, expanded newborn screening programs, and greater collaboration between stakeholders to improve access and affordability.

How Are Innovations in Gene Therapy and Immunotherapy Transforming PID Treatment?

Technological advancements in gene therapy and immunomodulatory treatments are reshaping the landscape of PID management, offering curative and targeted therapeutic approaches. Gene therapy has shown promising results in correcting underlying genetic mutations responsible for severe PIDs, such as Severe Combined Immunodeficiency (SCID) and Chronic Granulomatous Disease (CGD), reducing the need for lifelong IVIG therapy. The development of monoclonal antibodies and cytokine-based therapies is further expanding treatment options, helping to regulate immune function in patients with specific immunodeficiency subtypes. Additionally, advancements in precision medicine are enabling better patient stratification, ensuring that individuals receive the most effective therapy based on their genetic profile. AI-driven diagnostic tools and next-generation sequencing (NGS) are improving early detection and risk assessment, facilitating proactive treatment planning. The integration of telehealth and digital patient monitoring is also enhancing disease management, allowing healthcare providers to track patient responses to treatment in real time. As these innovations continue to progress, the future of PID treatment is becoming increasingly personalized and effective.

What Is Driving the Growth of the Primary Immunodeficiency Disorders Market?

The growth in the primary immunodeficiency disorders market is driven by several factors, including increasing awareness of rare immune disorders, advancements in genetic diagnostics, and expanding treatment options. The rising prevalence of diagnosed PID cases, facilitated by improved screening programs, is contributing to higher demand for immunoglobulin therapy and targeted biologics. Government initiatives supporting rare disease research and orphan drug development are further accelerating market expansion, encouraging pharmaceutical companies to invest in novel therapies. The growing adoption of cell and gene therapy approaches is also reshaping the PID treatment landscape, offering potentially curative solutions for severe cases. Additionally, patient advocacy organizations and non-profit initiatives are playing a key role in driving research funding, enhancing access to diagnostic services, and improving disease awareness. As treatment innovations and global healthcare policies continue to evolve, the primary immunodeficiency disorders market is expected to see substantial growth, paving the way for more effective and accessible care solutions.

SCOPE OF STUDY:

The report analyzes the Primary Immunodeficiency Disorders market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy, Other Treatment Types); Disease Type (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Other Disease Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • ADMA Biologics
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • CSL Behring LLC
  • GC Biopharma
  • Grifols S.A.
  • Horizon Therapeutics plc
  • Kedrion Biopharma Inc.
  • LFB S.A.
  • Lupin Pharmaceuticals
  • Merck KGaA
  • Novartis International AG
  • Octapharma AG
  • Pharming Group N.V.
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Primary Immunodeficiency Disorders - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence and Improved Diagnosis of Rare Immunodeficiencies Throws the Spotlight on Market Expansion Opportunities
    • Growth in Newborn Screening Programs and Early Detection Initiatives Drives Adoption of Life-Saving Therapies for PIDs
    • Advancements in Genetic Testing and Next-Generation Sequencing Expand Addressable Market Through Precise Diagnosis
    • Increased Availability of Immunoglobulin Replacement Therapies Drives Adoption of Long-Term Disease Management Strategies
    • Emergence of Subcutaneous Immunoglobulin (SCIG) Products Strengthens Business Case for Home-Based Treatment Modalities
    • Surge in Research on Monogenic Immune Disorders Spurs Growth in Targeted Therapeutic Development
    • Expansion of Orphan Drug Designation and Regulatory Incentives Propels Investment in Novel PID Treatments
    • Rising Use of Hematopoietic Stem Cell Transplantation (HSCT) in Severe PID Cases Enhances Treatment Landscape Complexity
    • Integration of Gene Therapy Platforms Generates Breakthrough Opportunities in Curative PID Interventions
    • Improved Physician Awareness and Educational Outreach Drives Early Intervention and Therapy Uptake
    • Increasing Support from Patient Advocacy Organizations Accelerates Public Policy Engagement and Access to Therapies
    • Development of Long-Acting Immunoglobulin Formulations Drives Convenience-Oriented Innovation in PID Care
    • Expansion of Specialty Pharmacies and Infusion Centers Strengthens Supply Chain for Advanced PID Treatments
    • Growing Application of Personalized Medicine Approaches Spurs Customized Immunomodulatory Therapies
    • Adoption of AI-Driven Clinical Decision Support Tools Enhances Diagnostic Accuracy and Treatment Optimization
    • Rising Government and Non-Profit Funding for Rare Disease Research Generates Pipeline Momentum
    • Emergence of Combination Immunotherapy Strategies Drives Clinical Trials in Complex Immune Dysregulation Disorders
    • Challenges in Reimbursement and Treatment Cost Justification Create Demand for Health-Economic Evidence
    • Globalization of Clinical Trials Expands Therapeutic Availability and Regional Market Penetration
    • Focus on Pediatric Patient-Centric Formulations and Administration Routes Enhances Compliance and Treatment Outcomes
    • Digital Health Integration in PID Patient Monitoring and Adherence Management Sustains Market Growth
    • Post-COVID Emphasis on Immune Health Drives Increased Vigilance and Screening for Underlying Immune Deficiencies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Primary Immunodeficiency Disorders Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Primary Immunodeficiency Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunoglobulin Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunoglobulin Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Immunoglobulin Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Antibiotic Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Stem Cell / Bone Marrow Transplantation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Stem Cell / Bone Marrow Transplantation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Stem Cell / Bone Marrow Transplantation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Antibody Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Antibody Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Antibody Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cellular Immunodeficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cellular Immunodeficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Cellular Immunodeficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Innate Immune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Innate Immune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Innate Immune Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • CHINA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Primary Immunodeficiency Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • INDIA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Primary Immunodeficiency Disorders by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Primary Immunodeficiency Disorders by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030

IV. COMPETITION